The Motley Fool

Two dirt-cheap FTSE 100 high-yield stocks for bargain hunters

Image source: Getty Images.

Even as earnings growth and reassuring global economic tailwinds propel many major equity indices to record highs valuations, high investor confidence means many stock valuations are looking increasingly stretched. This is bad news for value investors who are finding their pickings increasingly slim. But there are a few UK large-cap stocks that still offer the Holy Grail of attractive valuations and high dividend payouts.

Diversifying its way to growth

One is pharma giant GlaxoSmithKline (LSE: GSK). Even though it hasn’t increased its dividend in three years as it digests a major acquisition, its shareholders are currently netting a 4.99% yield annually. Combined with a sedate valuation of just 14.2 times forward earnings, this means it’s one appearing on many value screens.

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…

And if you click here we’ll show you something that could be key to unlocking 5G’s full potential...

And while analysts aren’t expecting dividend payments to increase over the next two years, there’s solid income growth potential over the long term. If dividend payments are to resume marching upwards, much of the credit will be going to the group’s slew of new drugs just entering the market.

From a series of new HIV treatments, whose sales are already growing by double-digits, to promising shingles treatments, these new drugs helped send group-wide constant currency pharmaceuticals sales up 1% in the first half of the year. This came despite sales of its blockbuster asthma drug Advair slowly declined, as it comes off patent.

And as these new drugs find their footing in the market, the company can thank its other two divisions, vaccines and consumer health, for pushing overall group revenue up 4% in constant currency terms during the period to £7.3bn.

CEO Emma Walmsley has also listened to investors and is pushing through wide-ranging, cost-cutting exercises that are already improving operating margins. In H1, this led free cash flow to double to £0.8bn. With sales and profits moving in the right direction, GSK should have more money to play with in the medium term, used to pay down debt, make further acquisitions, or juice shareholder returns.

Either way, now could be an interesting time to take a closer look at the pharma giant.

Far from dead in the water 

Another FTSE 100 stock offering index-beating income is Royal Mail Group (LSE: RMG), and its 5% dividend yield. Even though the company’s share price has risen a respectable 20% over the past year, its shares still trade at an attractive 12.1 times forward earnings.

Of course, this low valuation isn’t without good reason as the continued decline in the volume of letters being posted eats away at Royal Mail’s sales and profits. However, the management team, like the rest of us, hasn’t been surprised by this trend and is bulking up its position in the market for parcel delivery.

Last year, rapid growth in its UK and European parcel business helped boost group-wide revenue by 2% to £10.1bn, despite a 4% drop in letter revenue. This overall performance was impressive given UK letters still accounted for around 40% of overall revenue.

For the time being, the steady decline in letter volumes will keep Royal Mail growing slowly. But investments in automated sorting facilities are already having a positive effect on margins and hold the promise of further profit and dividend growth in the future. While Royal Mail is unlikely to ever deliver magnificent returns, its steady but dependable growth could appeal to value investors.

“This Stock Could Be Like Buying Amazon in 1997”

I'm sure you'll agree that's quite the statement from Motley Fool Co-Founder Tom Gardner.

But since our US analyst team first recommended shares in this unique tech stock back in 2016, the value has soared.

What's more, we firmly believe there's still plenty of upside in its future. In fact, even throughout the current coronavirus crisis, its performance has been beating Wall St expectations.

And right now, we're giving you a chance to discover exactly what has got our analysts all fired up about this niche industry phenomenon, in our FREE special report, A Top US Share From The Motley Fool.

Click here to claim your copy now — and we’ll tell you the name of this Top US Share… free of charge!

Ian Pierce has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

The renowned analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply enter your email address below to discover how you can take advantage of this.

I would like to receive emails from you about product information and offers from The Fool and its business partners. Each of these emails will provide a link to unsubscribe from future emails. More information about how The Fool collects, stores, and handles personal data is available in its Privacy Statement.